Pharma News News 14 December 2025

Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

December 18, 2025 — Insmed Incorporated (NASDAQ: INSM) shares dropped sharply Thursday after the company disclosed a Phase 2b setback for brensocatib in a chronic sinus condition and said it is discontinuing development in that indication, even as it simultaneously

18 December 2025

Johnson & Johnson Stock After Hours (Dec. 17, 2025): JNJ Closes Higher on FDA News—What to Know Before the Market Opens Thursday

Johnson & Johnson (NYSE: JNJ) ended Wednesday’s session modestly higher—an eye-catching show of relative strength on a down day for major U.S. indexes—while investors digested a fresh FDA approval tied to the company’s lung cancer franchise and looked ahead to

18 December 2025

FDA Updates · Financial Analysis · Investing · Pharma News · Stock Market

Eli Lilly Stock News Today (Dec. 17, 2025): LLY Holds Near Record Highs as Analysts Lift Targets and Obesity Pipeline Momentum Builds

Eli Lilly and Company (NYSE: LLY) stock traded in the mid-$1,050s in U.S. session Wednesday, December 17, 2025, hovering near recent highs as investors weighed fresh analyst commentary and new partnership headlines against an already-strong run for the pharma giant.

17 December 2025

Company Analysis · Health Industry · Investment · Pharma News · Stock Market

GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

Updated: 17 December 2025 GSK plc stock (LSE: GSK; NYSE: GSK) is in focus on Dec. 17 after a major U.S. regulatory win: the FDA approved Exdensur (depemokimab‑ulaa) for severe asthma—giving GSK a new, ultra‑long‑acting biologic that’s dosed just twice

17 December 2025

FDA Approvals · Investment Analysis · Pharma News · Stock Market

Pfizer Stock After Hours Today (Dec. 16, 2025): PFE Drops on 2026 Outlook—What to Know Before the Market Opens Dec. 17

Pfizer Inc. (NYSE: PFE) finished Tuesday’s session sharply lower after investors digested the company’s newly issued full‑year 2026 financial guidance—and the market’s message was clear: Wall Street wants more certainty on when Pfizer’s post‑COVID growth engine fully re-ignites. Pfizer stock

16 December 2025

Financial Reports · Investing · Market Analysis · Pharma News · Stock Market

Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight on Tuesday, December 16, 2025, as investors weigh a fresh Bank of America upgrade, a renewed value debate around the stock’s multiple, and a growing list of 2026 pipeline catalysts

16 December 2025

Dividend Stocks · Investment Strategies · Market Analysis · Pharma News · Stock Market

Amgen Stock (AMGN) News Today, Dec. 16, 2025: Dividend Boost, FDA Wins, Analyst Targets, and Key 2026 Catalysts

Amgen Inc. (NASDAQ: AMGN) is in focus on December 16, 2025, as investors weigh a fresh dividend raise, recent regulatory momentum, and a pipeline narrative that stretches from cardiovascular outcomes to the high-stakes obesity race. As of Dec. 16, 2025

16 December 2025

Dividends · Financial Analysis · Investing · Pharma News · Stock Market

Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open

Johnson & Johnson (NYSE: JNJ) shares finished Monday, December 15, 2025 higher and held modest gains in extended trading — a notable showing for a defensive blue chip as investors brace for a data-heavy week and shifting rate expectations. JNJ

16 December 2025

FDA Updates · Financial Analysis · Investing · Pharma News · Stock Market

Amicus Therapeutics (FOLD) Stock News Today: DMX-200 Trial Milestone, 52-Week High Momentum, and Analyst Forecasts (Dec. 15, 2025)

Amicus Therapeutics, Inc. (Nasdaq: FOLD) is back on investors’ radar as the rare-disease biotech extends a strong 2025 run—helped by a milestone quarter of GAAP profitability, expanding global launches for its Pompe franchise, and fresh news tied to a Phase

15 December 2025

Biotech Updates · Financial Forecasts · Investment Analysis · Pharma News · Stock Market

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead GSK plc stock (LSE: GSK, NYSE: GSK) is ending 2025 with a rare “cluster” of market-moving catalysts

15 December 2025

Biotech Forecasts · FDA Updates · Investment Analysis · Pharma News · Stock Market

Corona Remedies Share Price Today (15 Dec 2025): Pharma Stock Debuts at 38% Premium After ₹655-Crore IPO — Latest News, Forecasts, Valuation and Analyst Views

New Delhi / Mumbai, December 15, 2025 — Corona Remedies Limited, the Ahmedabad-headquartered branded pharmaceutical formulations company (not the beer), hit Dalal Street with a headline-worthy debut on Monday: the stock listed at a 38%+ premium to its IPO price,

15 December 2025

Financial Analysis · Investment Tips · IPO Updates · Pharma News · Stock Market

Merck stock (MRK): News, dividend date, Keytruda updates and analyst forecasts to watch before the U.S. market opens Dec. 15, 2025

Merck & Co., Inc. (NYSE: MRK) heads into Monday’s U.S. session (December 15, 2025) with investors juggling a mix of near-term headlines and long-term franchise questions: a fresh dividend “reset” that makes Dec. 15 an important calendar day, ongoing scrutiny

14 December 2025

Dividends · Investing · Market Analysis · Pharma News · Stocks

Pharma News News 14 December 2025 - 18 December 2025